OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.
Stock data | 2024 | Change |
---|---|---|
Price | $0.0002 | N/A |
Market Cap | $4.71K | N/A |
Shares Outstanding | 23.56M | N/A |
Employees | 2.00 | N/A |